PDF(Sci-hub)
Abstract：
Micronucleus (MN) assay has been widely used as a biomarker of DNA damage, chromosomal instability, cancer risk and accelerated aging in many epidemiological studies. In this narrative review and meta-analysis we assessed the association between lymphocyte micronuclei (MNi) and cancers of the skin, blood, digestive tract, and prostate. The review identified nineteen studies with 717 disease subjects and 782 controls. Significant increases in MRi for MNi were observed in the following groups: subjects with blood cancer (MRi = 3.98; 95 % CI: 1.98-7.99; p = 0.000) and colorectal cancer (excluding IBD) (MRi = 2.69; 95 % CI: 1.82-3.98, p < 0.000). The results of this review suggest that lymphocyte MNi are a biomarker of DNA damage and chromosomal instability in people with haematological or colorectal cancers. However, the MRi for lymphocyte MNi in subjects with cancers of skin, prostate, esophagus was not significantly increased. More case-control and prospective studies are warranted to further verify the observed trends and to better understand the role of lymphocyte MNi as a biomarker of cancer risk in blood, skin, digestive tract and prostate.
摘要：
微核(MN)检测已被广泛用作DNA损伤的生物标志物,染色体不稳定,在许多流行病学研究中，癌症风险和加速衰老。在这篇叙述性综述和荟萃分析中，我们评估了淋巴细胞微核（MNi）与皮肤癌之间的关联，血,消化道，还有前列腺.该综述确定了19项研究，其中717名疾病受试者和782名对照。在以下组中观察到MNi的MRi显着增加：患有血癌的受试者（MRi=3.98；95％CI：1.98-7.99；p=0.000）和结直肠癌（不包括IBD）（MRi=2.69；95％CI：1.82-3.98，p<0.000）。这篇综述的结果表明，淋巴细胞MNi是血液或结直肠癌患者DNA损伤和染色体不稳定的生物标志物。然而,皮肤癌患者淋巴细胞MNi的MRi，前列腺,食道没有明显增加。有必要进行更多的病例对照和前瞻性研究，以进一步验证观察到的趋势，并更好地了解淋巴细胞MNi作为血液中癌症风险的生物标志物的作用。皮肤,消化道和前列腺。
